Introduction {#sec1_1}
============

Syringomas are benign adnexal tumors of eccrine origin, mostly found in young to middle-aged women. The lesions presented as multiple, small, yellowish or skin-colored papules, often less than 3 mm and usually at the periorbital area. Unusual primary morphologies of syringomas, including lichen planus-like, milium-like and plaque-type syringomas, have been observed with possible distinct pathophysiology. We herein report a case of plaque-type syringoma which is a rare form of syringoma and 12 cases have so far been reported.

Case Report {#sec1_2}
===========

A 40-year-old Thai male from Bangkok came to the dermatology outpatient clinic with a history of multiple asymptomatic flesh-colored papules, which had slowly increased in number and coalesced into plaques, on both infraorbital regions, for 5 years. He denied a history of previous treatment. There was no other abnormal systemic symptom nor was there a family history of a similar skin condition.

Physical examination showed bilateral symmetrical ill-defined skin-colored plaques, 1.5--2 cm in diameter, with peripheral multiple 1--2 mm skin-colored papules on both infraorbital areas (Fig. [1](#F1){ref-type="fig"}). Hair and nails were normal with no mucosal involvement.

The histopathologic section from the left cheek revealed benign proliferation of eccrine ductal structures in the dermis with surrounding fibrotic stroma (Fig. [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). No perineural invasion or nuclear atypia was seen. The diagnosis was plaque-type syringoma. As the lesion was benign, the patient decided to observe the lesion without any treatment.

Discussion {#sec1_3}
==========

Syringomas are benign eccrine sweat gland tumors which present as multiple, small, yellowish or skin-colored papules, usually at the periorbital area; however, genitalia, trunk, scalp and acral sites have been reported \[[@B1], [@B2], [@B3]\]. Four clinical variants of syringomas have been proposed in 1987: localized, generalized, Down\'s syndrome-associated and familial form \[[@B4]\]. Uncommon types include lichen planus-like, milium-like and plaque-type syringomas. Plaque-type syringoma was first described in 1979 by Kikuchi et al. \[[@B6]\]; thereafter, 12 cases have been further reported on the face, neck, trunk, penis, and acral areas. More than half of the patients were female with unilateral distribution \[[@B5], [@B6], [@B7], [@B8], [@B9], [@B10]\]. Histopathologic examination demonstrates collections of small tadpole-shaped tubular structures, lined by single or double row of cuboidal epithelial cells, in the upper dermis \[[@B3], [@B6]\]. Plaque-type syringomas should be differentiated histologically from desmoplastic trichoepithelioma (DTE), morpheaform basal cell carcinoma (BCC), and microcystic adnexal carcinoma (MAC) in order to prevent unnecessary and extensive surgical procedures \[[@B5], [@B7], [@B10]\]. MAC is difficult to differentiate from plaque-type syringoma. Adequate tissue sampling is very important. Ductal structures in MAC are lined by asymmetric single cells. Presentation of perineural invasion is seen in MAC. MAC usually involves the dermis, subcutis and sometimes muscle, cartilage, and bone, whereas plaque-type syringoma is mostly limited to the upper dermis \[[@B5], [@B7]\]. Only one report of plaque-type syringoma of the penis with involvement of the deep reticular dermis has been reported so far \[[@B9]\]. DTE and morpheaform BCC can be differentiated from plaque-type syringoma from the lack of ductal differentiation. DTE often contains Merkel cells which stain positive for cytokeratin-20 and morpheaform BCC has features of nuclear atypia and mitoses \[[@B5], [@B7]\]. The histopathologic section from our patient showed no features suggesting MAC, DTE or morpheaform BCC.

Treatments of syringomas are for cosmetic concern and remain challenging. CO~2~ laser is the most effective treatment from current available data, but it does not give complete resolution. TCA peels could be used to combine with CO~2~ laser to increase efficacy \[[@B2]\].
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![Bilateral symmetrical ill-defined skin-colored plaques, 1.5--2 cm in diameter, with peripheral multiple 1- to 2-mm skin-colored papules on both infraorbital areas.](cde-0009-0190-g01){#F1}

![Hematoxylin and eosin, ×10. Proliferation of eccrine ductal structures in the dermis with surrounding fibrotic stroma.](cde-0009-0190-g02){#F2}

![Hematoxylin and eosin, ×40. The wall of the ducts is lined by 2 rows of cuboidal cells with comma-like tails.](cde-0009-0190-g03){#F3}
